StockData

Exozymes Inc. (EXOZ) shareholders

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.31−0.68 (-17.04%)

Close on Nov 17, 2026Market cap $30.72MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1.3%
0M of 9M shares
Institutional holders
9
2 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 3 sales
Net sold $28.45K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Christopher A. Marlett
Joint filing with Anthony DiGiandomenico (43.61%), MDB Capital Holdings, LLC (43.41%)
4,155,90443.61%13D (active)Nov 14, 2024
Tyler Korman832,5698.74%13D (active)Nov 14, 2024
Paul Opgenorth744,3337.81%13D (active)Nov 14, 2024
James U Bowie597,3886.27%13D (active)Nov 14, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of EXOZValueChange% of portfolio
Vanguard Capital Management LLC54,9850.59%$463.52K+32,7950.00%
Davidson Kahn Capital Management, LLC25,0000.27%$210.75KNew0.09%
Geode Capital Management, LLC23,4060.25%$197.31K+1,5150.00%
BlackRock, Inc.9,6100.10%$81.01K+2,8130.00%
Vanguard Fiduciary Trust Co9,4260.10%$79.46K–0.00%
Morgan Stanley1,2500.01%$10.54K–0.00%
Tower Research Capital LLC (TRC)3490.00%$2.94K−9680.00%
UBS Group AG2030.00%$1.71K+1790.00%
Barclays PLC750.00%$632New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202690M1.3%2 / 41 / 00M0M
Q1 202670M0.7%2 / 31 / 10M0M
Q4 202570M0.7%1 / 32 / 00M0M
Q3 202560M0.6%0 / 32 / 30M0M
Q2 202590M0.8%3 / 42 / 00M0M
Q1 202560M0.8%1 / 32 / 20M0M
Q4 202470M1.1%7 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

9 funds held EXOZ in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of EXOZValue% of fundAs of
Vanguard Total Stock Market Index Fund25,8790.28%$218.16K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund22,3420.24%$188.34K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund10,3110.11%$100.53K0.00%May 31, 2026
iShares Micro-Cap ETF9,1670.10%$77.28K0.01%Jun 30, 2026
Fidelity Series Total Market Index Fund2,9440.03%$28.70K0.00%May 31, 2026
Fidelity Total Market Index Fund2,0180.02%$19.68K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund1,9970.02%$19.47K0.00%May 31, 2026
1290 VT Micro Cap Portfolio4430.00%$3.73K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mohammad HayatPresident & Chairman of Board, Director155,8181.68%Nov 18, 2024
Damien Alan PerrimanChief Commercial Officer28,6920.31%Oct 26, 2026
Tyler Paz KormanChief Scientific Officer729,1237.86%Oct 21, 2026
Fouad NawazVice President- Finance9,4880.10%Sep 17, 2026
Michael HeltzenChief Executive Officer14,7080.16%Sep 2, 2026
Paul Hideo OpgenorthVice President, Development645,1496.95%Apr 8, 2026
Edgardo Javier RayoDirector77,9090.84%Oct 19, 2026
Anthony DigiandomenicoDirector, 10% owner3,808,47641.03%Oct 19, 2026
Lon E. BellDirector––Oct 19, 2026
Christopher A. MarlettDirector, 10% owner3,808,47641.03%Oct 19, 2026
James Joseph LalondeDirector––Oct 19, 2026
James Ulrich BowieDirector577,9106.23%Oct 19, 2026
MDB Capital Holdings, LLC10% owner3,931,13342.36%Nov 18, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Damien Alan Perriman
Chief Commercial Officer
Oct 12, 2026Sale−3,729$5.21$19.43K28,692
Damien Alan Perriman
Chief Commercial Officer
Oct 9, 2026Option exercise+3,922––32,421
Michael Heltzen
Chief Executive Officer
Aug 26, 2026Buy+4$7.58$3014,708
Michael Heltzen
Chief Executive Officer
Aug 26, 2026Buy+250$7.60$1.90K14,453
Michael Heltzen
Chief Executive Officer
Aug 26, 2026Buy+251$7.35$1.84K14,704
Michael Heltzen
Chief Executive Officer
Aug 25, 2026Buy+250$7.52$1.88K14,203
Michael Heltzen
Chief Executive Officer
Aug 25, 2026Buy+100$7.50$75013,953
Michael Heltzen
Chief Executive Officer
Aug 19, 2026Award+8,841$6.40$56.58K13,853
Tyler Paz Korman
Chief Scientific Officer
Aug 19, 2026Option exercise+32,964––762,837
Damien Alan Perriman
Chief Commercial Officer
Aug 19, 2026Option exercise+19,612––28,499
Tyler Paz Korman
Chief Scientific Officer
Apr 9, 2026Sale−750$10.53$7.90K729,123
Tyler Paz Korman
Chief Scientific Officer
Apr 8, 2026Sale−750$10.04$7.53K729,873
Damien Alan Perriman
Chief Commercial Officer
Apr 1, 2026Award+62,759––62,759
Tyler Paz Korman
Chief Scientific Officer
Apr 1, 2026Award+5,332$8.44$45.00K730,623
Paul Hideo Opgenorth
Vice President, Development
Apr 1, 2026Award+3,999$8.44$33.75K645,149
Damien Alan Perriman
Chief Commercial Officer
Apr 1, 2026Award+8,887$8.44$75.01K0
Fouad Nawaz
Vice President- Finance
Apr 1, 2026Award+5,999$8.44$50.63K9,488
Michael Heltzen
Chief Executive Officer
Jul 2, 2025Buy+1,040$10.22$10.63K10,629
Tyler Paz Korman
Vice President, Research
Jun 16, 2025Award+2,990$12.54$37.49K725,291
Paul Hideo Opgenorth
Vice President, Development
Jun 13, 2025Award+2,990$12.54$37.49K641,150
Fouad Nawaz
Vice President, Finance
Jun 13, 2025Award+3,489$12.54$43.75K3,489
Michael Heltzen
Chief Executive Officer
Jan 17, 2025Buy+1,767$10.78$19.05K3,872
Michael Heltzen
Chief Executive Officer
Jan 16, 2025Buy+121$10.72$1.30K2,105
Michael Heltzen
Chief Executive Officer
Nov 15, 2024Buy+1,984$11.10$22.02K1,984
MDB Capital Holdings, LLC
10% owner
Nov 8, 2024Conversion+122,657$6.40$785.00K3,931,133
Paul Hideo Opgenorth
Vice President, Development
Nov 8, 2024Conversion+2,344$6.40$15.00K640,504

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.67%
0M shares short
Days to cover
1.2
At 0M shares a day
Change since last report
+1.3%
From 0M shares
Short volume, 20 days
25.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Exozymes's stock actually held short. Settlement fails (shares not delivered on time) peaked at 752 shares on Sep 9, 2026 over the last 90 days.

See a number that looks wrong?